Finance

Beta
Lists
ATAI:NASDAQ
AtaiBeckley Inc
$5.29
+15.50%
(+0.71) 1D
$5.31
+0.38% (+0.020)
After hours
Closed: Jun 26, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ATAI...
Open
$4.50
High
$5.31
Low
$4.42
Mkt. cap
1.95B
Avg. vol.
5.34M
Volume
63.24M
52-wk high
$6.72
52-wk low
$2.15
EPS
-$2.23
Beta
1.60
Shares outstanding
368.17M
No. of employees
99
Open
$4.50
High
$5.31
Low
$4.42
Mkt. cap
1.95B
Avg. vol.
5.34M
Volume
63.24M
52-wk high
$6.72
52-wk low
$2.15
EPS
-$2.23
Beta
1.60
Shares outstanding
368.17M
No. of employees
99
News stories
From sources across the web
Profile
AtaiBeckley Inc. is a clinical-stage biotechnology company developing treatments for mental health disorders, including therapies based on psychedelics, entactogens, and related compounds. The company was founded in November 2025 through the combination of atai Life Sciences N.V. and Beckley Psytech Limited. atai Life Sciences was founded in 2018 and became a publicly listed company in 2021. Beckley Psytech, a private company, was founded in 2019. In December 2025, the combined company redomiciled from the Netherlands to the U.S., incorporated in Delaware and headquartered in New York, NY. The company's shares trade on the Nasdaq stock exchange under the ticker symbol ATAI. The company's pharmaceutical candidates include mebufotenin for treatment-resistant depression, dimethyltryptamine for treatment-resistant depression, and-midomafetamine for social anxiety disorder. The company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and treatment-resistant depression. Wikipedia
About AtaiBeckley Inc
CEOFlorian Brand
Employees99
Founded2018
Headquarters-
SectorPharmaceutical industry
Websiteataibeckley.com
Analyst ratings
Based on 8 analysts giving stock ratings to ATAI in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for ATAI in the last 3 months.
Highest
Current $5.29
$25.00 (+372.59%)
Average
$16.71 (+215.88%)
Lowest
$14.00 (+164.65%)
Analyst
Recommendation
Action
Price target
Projected
Date
Justin Walsh
JonesTrading
Buy
Maintained
$16.00
+202.5%
06/25/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$25.00
+372.6%
06/25/2026
Ritu Baral
TD Cowen
Buy
Maintained
-
-
05/13/2026
Sumant Kulkarni
Canaccord Genuity
Buy
Reiterated
$15.00
+183.6%
05/13/2026
Ami Fadia
Needham
Buy
Reiterated
$15.00
+183.6%
05/13/2026
Harry Gillis
Berenberg Bank
Buy
Maintained
$14.00
+164.7%
04/20/2026
Eddie Hickman
Guggenheim
Buy
Reiterated
$16.00
+202.5%
04/16/2026
Jay Olson
Oppenheimer
Buy
Reiterated
$16.00
+202.5%
04/05/2026
David Hoang
Deutsche Bank
Buy
Initiated
$12.00
+126.8%
03/26/2026
Michael Okunewitch
Maxim Group
Buy
Reiterated
$10.00
+89%
03/17/2026
Andrew Tsai
Jefferies
Buy
Maintained
$10.00
+89%
03/09/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
719.00K
749.00K
1.07M
954.00K
Cost of goods sold
10.51M
14.68M
14.91M
17.32M
Cost of revenue
10.51M
14.68M
14.91M
17.32M
Research and development expenses
582.00K
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
14.90M
14.50M
24.40M
14.53M
Operating expense
15.48M
14.50M
24.40M
14.53M
Total operating expenses
25.99M
29.18M
39.32M
31.86M
Operating income
-25.27M
-28.44M
-38.25M
-30.90M
Other non operating income
-6.33M
-51.25M
13.99M
4.10M
EBT including unusual items
-27.68M
-61.00M
-544.84M
-30.52M
EBT excluding unusual items
-30.16M
-79.20M
-23.71M
-27.13M
Income tax expense
65.00K
102.00K
3.00K
-722.00K
Effective tax rate
-0.23%
-0.17%
-
2.37%
Other operating expenses
-
-
-
-
Net income
-27.73M
-61.07M
-544.81M
-29.78M
Net profit margin
-3,856.61%
-8,154.07%
-51,108.16%
-3,121.80%
Earnings per share
-0.14
-0.28
-1.73
-0.08
Interest and investment income
248.00K
504.00K
542.00K
78.00K
Interest expense
-264.00K
-
-
-
Net interest expenses
-16.00K
504.00K
542.00K
78.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-25.05M
-28.20M
-37.91M
-30.73M
Gain or loss from assets sale
-
-
692.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of ATAI
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer